Using the yeast one-hybrid approach to screen a human breast tissue hybrid cDNA expression library, we have found that four orphan/nuclear receptors, ERRa-1, EAR-2, COUP-TFI (EAR-3), and RARg, bind to the silencer (S1) region of the human aromatase gene. S1 down regulates promoters I.3 and II of the human aromatase gene. In this study, the interaction of EAR-2, COUP-TFI, and RARg with S1 was con®rmed by DNA mobility shift analysis. In contrast to the ®ndings that ERRa-1 behaves as a positive regulatory factor, these three nuclear receptors were found, by mammalian cell transfection experiments, to act as negative regulatory factors by binding to S1. Furthermore, the negative action of these three nuclear receptors could override the positive eect of ERRa-1. RT ± PCR analysis of 11 cell lines and 55 human breast tumor specimens has shown that these nuclear receptors are expressed in human breast tissue. Since EAR-2, COUP-TFI, and RARg are expressed at high levels, it is likely that S1 is a negative regulatory element that suppresses aromatase promoters I.3 and II in normal breast tissue. In cancer tissue, S1 may function as a positive element since ERRa-1 is expressed, but EAR-2 and RARg are only present in a small number of tumor specimens. This hypothesis is sustained by the ®nding that there is a weak inverse correlation between the expression of COUP-TFI and that of aromatase in breast tumor tissue. Our studies have revealed that estrogen receptor alpha (ERa) can also bind to S1, in a liganddependent manner. By binding to S1, ERa downregulates the aromatase promoter activity. These results demonstrate that nuclear receptors play important roles in modulating aromatase expression in human breast tissue.
Introduction
The female hormone estrogen stimulates breast cancer cell growth. Aromatase converts androgen to estrogen. In situ estrogen formation plays an important role in breast cancer development. The control of human aromatase gene expression is complex in that several promoters direct aromatase gene expression in a tissue speci®c manner (Mahendroo et al., , 1993 Means et al., 1991; Harada, 1993; Harada et al., 1993) . Results from this and other laboratories suggest that promoters I.3 and II are the major promoters directing aromatase expression in breast cancer tissue and in surrounding adipose stromal cells Harada, 1997; Bulun et al., 1997) . Our laboratory has identi®ed a silencer element (S1) that is situated between promoters I.3 and II . Our results suggest that S1 down regulates the action of the two promoters in normal breast tissue, and its negative activity is overcome by a cAMP-dependent mechanism in breast cancer tissue (Zhou and Chen, 1999) . In order to better understand the action of S1, we utilized yeast onehybrid screening methods to identify transcription factors that interact with S1 in human breast tissue. Most proteins detected by this approach belong to the nuclear receptor superfamily. Fifty per cent of the positive clones encode for ERRa-1, and other positive clones include EAR-2, EAR-3 (COUP-TFI), RARg, and p120E4F. Previously, we examined and reported the positive regulatory action of ERRa-1 on promoter I.3 of the human aromatase gene (Yang et al., 1998) . In contrast to the previous ®ndings on ERRa-1, we have now found that EAR-2, COUP-TFI, and RARg function as negative regulatory factors by binding to S1. In addition, estrogen receptor a (ERa), an important nuclear receptor in human breast tissue, has also been found to be able to bind to S1 in the 17b-estradiol (E 2 )-dependent manner, leading to a down regulation of the aromatase promoter activity. The results obtained from recent studies with EAR-2, COUP-TFI, RARg, and ERa are presented and discussed in this report.
Results
Demonstration of the binding of nuclear receptors to S1 by DNA mobility shift analysis DNA footprinting analysis has revealed that ERRa-1 binds to S1 at the region with the sequence 5'-AAGGTCAGAAAT-3' (Yang et al., 1998) . EAR-2, COUP-TFI, and RARg are known to recognize the identical cis-element (Klinge et al., 1997; Nakshatri and Bhat-Nakshatri, 1998) . Formation of S1-nuclear receptor complexes was observed by DNA mobility shift analysis (Figure 1 ). Nuclear receptors were generated using an in vitro transcription/translation method (described in Materials and methods). The relative amounts of the translated ERRa-1 and EAR-2, COUP-TFI and RARg proteins were quanti®ed by [ 35 S] methionine incorporated into the expressed proteins which were separated on 10% SDS ± PAGE. Using ERRa-1 and COUP-TFI as the examples, the nuclear receptors were found to bind to S1 in a dosedependent manner ( Figure 1A ). COUP-TFI, RARg and EAR-2 bound signi®cantly weaker to S1 than ERRa-1. RARg-and EAR-2-DNA complexes were detected when the amounts of the receptors used were two and three times that of COUP-TFI, respectively ( Figure 1B ). These ®ndings agree with our results from the yeast one-hybrid screening. Our screen resulted in 13 clones of ERRa-1, 4 clones of EAR-2, 3 clones of COUP-TF1, and 3 clones of RARg (Yang et al., 1998) . The cloning frequency should correlate with the binding anity of transcription factors to the response element (i.e., S1) and the abundance of the positive clones in the mammary tissue cDNA library. A 50-fold molar excess of unlabeled S1 can compete with the binding of these nuclear receptors to the 32 P-labeled S1 ( Figure 1A ). However, a 50-fold molar excess of poly (dI-dC) could not compete with the binding (results not shown).
Determination of the regulatory activity of nuclear receptors by mammalian cell transfection experiments
To address the functional signi®cance of the interaction of EAR-2, COUP-TFI, and RARg with S1, we transfected the SK-BR-3 breast cancer cell line with their expression plasmids (pSG5 constructs) and a CAT reporter plasmid containing the aromatase genomic fragment that contains promoter I.3 and S1 (pums-64/+129CAT, as described by Zhou and Chen, 1999) . It was found that these three nuclear receptors behave as negative regulators, in a DNA dosedependent manner (Figure 2) . Interestingly, although as demonstrated by a gel mobility shift assay, EAR-2 and RARg have signi®cantly lower anity to S1 than COUP-TFI, the three nuclear receptors suppress promoter I.3 to a similar degree. These receptors were subcloned into the same expression plasmid, pSG5 (i.e. the expression was driven by the same promoter) and are thought to be expressed at similar levels in transfected cells. RARg acted as a negative regulator either in the presence or absence of the ligand retinoic acid (results not shown). In addition, the negative action of these three nuclear receptors was found to be capable of overriding the positive eect of ERRa-1 (Figure 3 ). Under our experimental conditions, EAR-2 was found to be less eective than COUP-TFI and RARg in competing with ERRa-1.
We have recently succeeded in preparing a Hep-G2 hepatoma cell line over expressing EAR-2 and Hep-G2 cell line over expressing COUP-TFI. The Hep-G2 cell line expresses aromatase and has higher transfection Figure 1 Gel mobility shift assay of the interaction of nuclear receptors with S1. (A) Dose-dependent interaction of ERRa-1 (lanes 1 ± 5) and COUP-TFI (lanes 6 ± 10) with S1. Each binding reaction contained a ®xed amount of in vitro translated protein and a decreasing amount of the 32 P-S1 probe as indicated about each lane. Samples loaded in lanes 1 and 6 also contained nonradioactive S1 probe whose concentration was 506those of the 32 P-labeled S1 in the sample loaded in lanes 2 and 7. (B) Gel mobility shift assay of the interaction of ERRa-1 (lane 1), COUP-TF1 (lane 2), EAR-2 (lane 3) and RARg (lane 4) with S1 (as indicated by arrows). Binding reactions were performed with 32 Plabeled S1 (at 1610 4 CPM/each reaction) and in vitro translated proteins at the indicated amounts (ERRa-1, 3 ml; COUP-TFI, 3 ml; EAR-2, 9 ml; RARg, 6 ml) following the procedures described in Materials and methods eciency in the cDNA transfection experiments than breast cancer lines. While this cell line expresses these two receptors endogenously, aromatase activity in the transfected cell lines were found to be signi®cantly lower than that in the untransfected cell line (Figure 4) . These results further support the hypothesis that EAR-2 and COUP-TFI are negative regulatory factors for aromatase expression.
Expression of nuclear receptors in human breast tissue and cell lines derived from the tissue Using RT ± PCR, we examined the expression of aromatase, EAR-2, COUP-TFI, RARg, ERRa-1, and SF-1 in two non-cancer breast epithelial cell lines (MCF-10A, HBL-100), ®ve breast ®broblast cell lines (WS3PF, WS3TF, GI33PF, GI33TF, and W88-TF), three breast cancer cell lines (MCF-7, SK-BR-3, and MDA-MB-231), one hepatoma cell line (Hep-G2), and 55 breast cancer specimens. The results generated with the cell lines are summarized in Figure 5 and discussed below. Under the conditions described in Materials and methods, aromatase mRNA was clearly detected in only MCF-7, SK-BR-3, and Hep-G2 cell lines. EAR-2 expression was found high in MCF-10A and HBL-100 cell lines and signi®cantly lower in ®broblasts. EAR-2 mRNA was also detected in SK-BR-3, MDA-MB-231, and Hep-G2 cell lines. COUP-TFI was found to be Figure 2 Negative regulatory eects of proteins EAR-2, COUP-TFI and RARg on aromatase promoter 1.3 activity in SK-BR-3 cells. Transient transfection experiments in SK-BR-3 cells were performed with 2 mg of the CAT reporter plasmid (pums-64/+129) and expression plasmids pSG5-EAR-2, pSG5-COUP-TF1 and pSG5-hRARg at the indicated amounts. The cells were harvested 72 h after transfection. The cell lysates were prepared and analysed for CAT activity. The overall amount of total DNA in all transfections were equalized by including appropriate amounts of empty vector, pSG5 in addition to speci®c amounts of the test plasmids indicated in each experiment. The CAT activity in cells transfected with only the empty vector and the CAT reporter plasmid was taken as 100%. The results shown are mean activities plus standard deviations of three independent transfection experiments. When the results from nuclear receptor-transfected samples were compared with the pSG5 vector-transfected controls, the dierences were found to be statistically signi®cant (P50.01) Figure 3 Suppression of the transactivation activity of ERRa-1 on promoter I.3 by EAR-2, COUP-TFI and RARg in SK-BR-3 cells. The cells were co-transfected with 2 mg of pums-64/+129, 3 mg of the ERRa-1 expression plasmid (pSG5-hERRa1) and one of the three expression plasmids pSG5-EAR-2, pSG5-COUP-TFI and pSG5-hRARg at three dierent amounts (1 mg, 2 mg and 3 mg). The CAT activity in cells transfected with the CAT reporter construct and pSG5-hERRa1 were taken as 100%. The results shown are mean activities plus standard deviations of three independent transfection experiments. When the results from nuclear receptor-transfected samples were compared with the pSG5-hERRa1-transfected controls, the dierences were found to be statistically signi®cant (P50.01) Figure 4 Down regulation of aromatase expression in COUP-TFI-over expressing and EAR-2-over expressing Hep-G2 cells. Hep-G2 cells were transfected with the mammalian expression vector pRC/CMV, pRC/CMV-EAR-2 or pRC/CMV-COUP-TFI plasmids. The stable expression cell lines were prepared through G418 selection (see Materials and methods). The aromatase activity of 100% was de®ned as the activity in transfectant Hep-G2 cells with the empty vehicle pRC/CMV only high in the MCF-10A and HBL-100 cell lines, and also detected in ®ve ®broblast cell lines, MCF-7, MDA-MB-231, and Hep-G2 cell lines, at approximately half the levels observed in non-cancer breast epithelial cell lines. RARg was found to be high in MCF-10A and HBL-100 cell lines. RARg was also found to be expressed in three breast cancer cell lines, but not in ®broblast lines. ERRa-1 was detected in all cell lines, and SF-1 was only detected in the Hep-G2 cell line.
Among 55 breast tumor specimens, aromatase mRNA was detected in 54 specimens, and ERRa-1 was detected in 23 specimens. The expression of RARg and EAR-2 was only found in 6 and 13 specimens, respectively. COUP-TFI was found to be expressed in 37 specimens. The expression level of COUP-TFI was found to have a weak inverse correlation with the expression level of aromatase in tumor specimens (P-value=0.07). A larger sample size is needed to further evaluate the signi®cance of the latter ®nding.
To summarize our RT ± PCR results, aromatase is expressed in breast cancer specimens and breast cancer cell lines. EAR-2 and RARg is expressed at high levels in non-cancer epithelial cells. COUP-TFI expression may negatively correlate with the expression of aromatase. ERRa-1 is expressed in some breast tumor tissues, and as reported before (Yang et al., 1998) , it was found that SF-1 was not expressed in breast tissue. Among these nuclear receptors, the ®broblast lines mainly express COUP-TFI and ERRa-1.
Demonstration and functional characterization of the interaction of ERa with S1
Since ERa is an important nuclear receptor in breast tissue and the S1 sequence 5'-AAGGTCAGAAAT-3' is an extended half-site estrogen response element (ERE), we have decided to determine whether ERa can bind to S1. The DNA mobility shift analysis revealed that in the presence of E 2 ERa bound to S1 ( Figure 6A ). The E 2 -dependent ERa-S1 interaction was con®rmed by the yeast one-hybrid assay ( Figure 6B ). The mammalian cell transfection experiments revealed that by binding to S1, ERa down-regulated the aromatase promoter activity ( Figure 7) . A fast migrating band was observed when the DNA mobility shift analysis was performed with ERa, but without E 2 ( Figure 6A ). The signi®cance of this result is not known.
Discussion
S1 was originally identi®ed to be a negative regulatory element that suppressed promoters I.3 and II of the human aromatase gene . We have found in this and previous studies (Yang et al., 1998) that at least six orphan/nuclear receptors can bind to S1; COUP-TFI, EAR-2, RARg and ERa have negative regulatory function, and ERRa-1 and SF-1 have positive regulatory function. While pseudopositive clones can be generated from the yeast onehybrid screen, the interaction of ERRa-1, EAR-2, COUP-TFI, and RARg with S1 was supported by the fact that our screen produced several clones of each receptor: 13 clones of ERRa-1, 4 clones of EAR-2, 3 clones of COUP-TFI, and 3 clones of RARg (Yang et al., 1998) . Furthermore, the cloning frequency should correlate with the binding anity of transcription factors to the response element (i.e., S1) and the abundance of the positive clones in the mammary tissue cDNA library. To support our cloning results, Figure 1 shows that COUP-TFI, RARg and EAR-2 bind signi®cantly more weakly to S1 than ERRa-1. In addition, to demonstrate the interaction of these nuclear receptors with S1, we have also performed transfection experiments to show that these nuclear receptors can modulate the promoter activity using a reporter construct containing S1 (Figure 2) . Finally, we (Figure 4 ) and the activity was increased in cells transfected with ERRa-1 (see Yang and Chen, 1999) . The aromatase expression in Hep-G2 is driven by promoters I.4, I.3, and II (unpublished results). Therefore, it is not unexpected that these nuclear receptors can modulate aromatase expression in Hep-G2 cells. These results lead us to conclude that the four nuclear receptors identi®ed from our screen of a mammary tissue cDNA library using the yeast onehybrid approach are the major factors interacting with S1 in human breast tissue. Although SF-1 binds strongly to S1 (see Yang et al., 1998) , this protein is not expressed in human breast tissue and we did not identify this protein in our yeast one-hybrid screen.
In the present investigation, we have also shown that the negative activity of COUP-TFI, EAR-2, and RARg can override the positive activity of ERRa-1, agreeing with the ®nding that most of the time, S1 behaves as a negative regulatory element in human breast. There are at least two possible mechanisms for the down regulation of the activity of ERRa-1 by COUP-TF1, EAR-2, and RARg. It can be achieved by a direct competition of the ERRa-1 binding to S1 by the other three nuclear receptors, supporting again the conclusion that all four nuclear receptors can bind to S1. A similar mechanism has been suggested to explain the interaction of SF-1 and COUP-TFI with S1 in endometrium (Zeitoun et al., 1999) . It is also possible that ERRa-1 forms heterodimers with the other three nuclear receptors, preventing the binding of ERRa-1 to S1. While heterodimer formation between nuclear receptors has been demonstrated (e.g., Klinge et al., 1997) , the physiological signi®cance of the heterodimeric nuclear receptors is not yet fully understood. Figure 7 Down regulation of the activity of promoter 1.3 through E 2 bound ERa. SK-BR-3 cells were cotransfected with pums-64/+129 (2 mg) and pSG5-ERa (3 mg). After 16 h, fresh media were introduced and E 2 at two dierent concentrations were added. After another 24-h incubation, the cells were lysed, and the reporter gene activity was measured. The results are shown as per cent CAT activity from two independent experiments with each concentration in triplicate. A 100% of the CAT activity is de®ned as the activity in transfected cells without treatment of E 2 Figure 6 (A) Gel mobility shift assays of the interaction of ERa with S1. Binding reactions were performed with 32 P-labeled S1 (at 1610 4 CPM/each reaction) and 3 ml of in vitro translated ERa protein with and without 5 mM of E 2 . (B) Evaluation of the interaction between ERa and S1 by the yeast one-hybrid assay. The experiments were performed using pACT2-ERa (i.e., ERa) and pLacZi-3S1 (i.e., S1-LacZ) following the procedures described in Materials and methods
Control of aromatase expression in breast tissue C Yang et al
We demonstrated the suppressive eect of RARg without co-transfection with RXR. It is thought that RARg may interact with the endogenous RXR in cells. The suppressive eect of RARg can also result from a prevention of the binding of a positive regulatory protein such as ERRa-1 by occupying the S1. Aromatase is expressed in breast cancer specimens and breast cancer cell lines, but not in non-cancer cell lines. The expression level of EAR-2 and RARg was found to be high in normal breast and low in cancer tissue. The expression of COUP-TFI may negatively correlate with the expression of aromatase in breast tumor tissue. These results support the notion that these three receptors negatively regulate the expression of aromatase.
Nuclear receptors such as ER and progesterone receptor (PR) are known to play critical roles in proliferation of human normal breast and cancer tissues, and have been extensively investigated. A few studies on retinoic acid receptors (RARs) were performed. There are three isoforms of RAR: alpha, beta, and gamma. The results obtained so far support the hypothesis that the expression of RARb is signi®cantly lower in breast cancer tissue than in normal breast tissue (Widschwendter et al., 1997) . Our RT ± PCR analysis has found that RARg is expressed at high levels in two non-cancer epithelial cell lines (MCF-10A and HBL-100), but in only 6 out of 55 breast cancer tissue specimens. These results suggest that the expression of this RAR isoform is also low in breast cancer tissue. In contrast to extensive studies of nuclear receptors such as ER, PR, and RAR in human normal breast and cancer tissues, there is relatively little known regarding the expression and function of orphan receptors in these tissues. Dotzlaw et al. (1999) have reported that the human orphan receptor PXR mRNA can be detected by RT ± PCR in both normal and neoplastic breast tissue. In the present study, we have examined the expression of ERRa-1, EAR-2, and COUP-TFI in breast cell lines and breast cancer tissue specimens.
ERRa-1 was shown to function through the ciselement as a transcriptional activator for several promoters, including osteopontin (OPN) promoter (Bonnelye et al., 1997) , and medium-chain acyl coenzyme A dehydrogenase (MCAD) promoter (Sladek et al., 1997), or as a transcriptional repressor for the SV40 late promoter in both cell culture and cellfree transcription systems (Johnston et al., 1997; Zho and Mertz, 1995) . EAR-2 has been shown to act as a silencer-binding protein for the human oxytocin gene promoter (Chu and Zingg, 1998) and a positive regulatory protein for the human apolipoprotein C-II gene (Vorgia et al., 1998) . COUP-TFI is shown to be a negative regulator of retinoic acid response pathways (Tran et al., 1992) , but a positive regulator of the trout estrogen receptor (Lazennec et al., 1997) . These published results indicate that for dierent gene promoters, these receptors can behave as either transcriptional activators or repressors. This may result from the interaction of these receptors with various coactivators or corepressors in dierent cell contexts.
Our results (Figure 6a ,b) demonstrate that ERa can also bind to S1. The binding of ERa to ERE half site has been reported by Klinge et al. (1997) and Vanacker et al. (1999) . As expected, the ligand E 2 was required for the functional ERa-S1 interaction. However, instead of promoter activation, the interaction resulted in a suppression of the promoter activity. It is thought that E 2 -ERa complex behaves as an antagonist that competes with positive regulatory proteins such as ERRa-1 for binding to S1. To test this hypothesis, we performed promoter functional analysis through ERa and ERRa-1 cotransfection experiments. We found that in a ligand-dependent manner, ERa could suppress the positive regulation by ERRa-1 (unpublished results). In addition, our yeast one-hybrid assay revealed that relatively high concentrations of estradiol (100 nM or higher) were required to facilitate the ERa-S1 interaction. Normally, ERa can be activated with 0.1 ± 1 nM of E 2 . While the exact nature of the ERa-S1 interaction is not yet known, it is thought that the binding anity of the ligand bound ERa to S1 is weaker than to an ERE. The K m value of the androgen substrate for human aromatase has been estimated between 40 ± 50 nM (e.g. Thompson and Siiteri, 1974; Kao et al., 1996) , and the K m value establishes an approximate value for the intracellular level of the substrate (Segel, 1976) . Therefore, the intracellular concentrations of androgen and estrogen in aromatase-expressing cells are probably near or lower than 50 nM. It is hypothesized that the down regulation of aromatase promoter activity by ERa through S1 is a feedback mechanism to suppress aromatase expression when the intracellular concentration of estrogen is near or higher than 100 nM. This hypothesis is supported by a study using baboon (Nakamura et al., 1999) . It was found that estrogen treatment in high doses down regulated aromatase mRNA and activity in breast tissue of the ovariectomized non-human primate. The results from the yeast one-hybrid assay ( Figure 6B ) also explain why ERa was not identi®ed when the yeast one-hybrid screen was performed in the absence of E 2 .
Our DNA footprinting analysis for the binding of ERRa-1 to the aromatase gene revealed a second binding site which is 59 bp upstream from S1. The nucleotide sequence of the second binding site is AAGGGCA, which diers by 1 bp from the ®rst site (i.e., AAGGTCA). DNA mobility shift experiments have revealed that the four nuclear receptors can also bind to the second site, and the interaction with the 32 P-labeled probe could be competed by unlabeled DNA fragments, but not by poly (dI-dC). This may be another regulatory element of the human aromatase gene. A detailed functional analysis of the second binding site is being performed.
It has been proposed by us that in normal breast stromal cells, aromatase expression is regulated by promoter I.4 mediated through glucocorticoid, and the action of promoter I.3 and II is suppressed by S1 . However, in cancer tissue, cAMP production increases and aromatase promoters are switched to cAMP-dependent promoters, i.e., I.3 and II. The present study provides additional results to explain the mechanism of promoter switching in breast tissue. It is thought that in normal breast tissue, S1 behaves as a negative regulatory region because it interacts with COUP-TFI, EAR-2, and RARg that are expressed at high levels. Furthermore, the negative regulatory properties of these three receptors can overcome the positive action of ERRa-1. In cancer tissue, the expression of these receptors decreases. S1 may behave as a positive regulatory element for promoters I.3 and II by interacting mainly with ERRa-1. Therefore, the positive and negative regulation of S1 and aromatase in breast tissue depends on the balance of receptor expression. In our previous publication, we noted that while the aromatase gene is ampli®ed in MCF-7 cells, the expression of aromatase is very low (Zhou et al., 1993) . Recent yeast one-hybrid screening of a MCF-7 library has revealed that the major protein interacting with S1 is COUP-TFII (Wu et al., unpublished results). The results obtained so far indicate that this receptor behaves as a repressor when it binds to S1, as would be predicted based on the low level of aromatase expression in MCF-7 cells.
In conclusion, nuclear receptors, including ERRa-1, EAR-2, COUP-TFI, RARg, and ERa regulate promoters I.3 and II of the human aromatase gene in breast tissue by interacting with a regulatory element, S1. COUP-TFI, EAR-2, RARg and ERa have negative regulatory functions, and ERRa-1 has a positive regulatory function. The regulatory action of S1 depends upon the expression level of these receptors in various tissues.
Materials and methods

Materials
DNA sequencing kits were from United States Biochemical (Cleveland, Ohio, USA). AMV reverse transcriptase, T4 kinase, T4 DNA ligase and various restriction endonuclease were purchased from New England Biolabs (Beverly, MA, USA) and Boehringer Mannheim (Indianapolis, IN, USA). AmpliTag polymerase was obtained from Perkin Elmer (Norwalk, CT, USA).
Chloramphenicol, speci®c radioactivity, 55 mCi/mmol) was from Amersham Life Science, Inc. (Arlington Heights, Illinois, USA). The CAT expression vector, pUMSVOCAT, was a gift from Dr K Kurachi at University of Michigan, Ann Arbor, Michigan. Oligonucleotide primers were synthesized in the DNA/RNA chemistry laboratory at the City of Hope. SK-BR-3 cells (ATCC, Rockville, MA, USA), derived from a human breast adenocarcinoma, were maintained in McCoy's 5A medium containing 10% fetal calf serum and glutamine. HepG2 cells, human hepatoblastoma cells from ATCC, were grown in Dulbecco's modi®ed Eagle's medium (Gibco, Grand Island, NY, USA) containing 1 mM Sodium Pyruvate. WS3PF, WS3TF, GI33PF, GI33TF, and W88-TF are human breast ®broblast cell lines and were gifts from Dr RJ Santen at University of Virginia Health Science Center, Charlottesville, VA. The ®broblast cell lines were maintained in Waymouth's MB 752/1 medium with 15% fetal calf serum.
Plasmid preparation
The construction of ERRa-1 expression plasmid pSG5-hERRa1 was described by Yang et al. (1998) . For preparing pSG5-EAR-2, the cDNA of EAR-2 was generated by PCR using two primers, 5'-GGCGAATTCGCCGCCGCCATGGC-CATGGTGACCGGC-3' (forward primer) and 5'-TAGAT-CTGGATCACTGGCCCGAGCCGTA-3' (reverse primer), and used pMT2-EAR-2 as template. The PCR product was ligated into pSG5 vector at the EcoRI and BamHI sites. For pSG5-COUP-TFI, the cDNA of COUP-TFI was cut from pMT2-COUP-TFI and then ligated into pSG5 vector at the EcoRI site. Both pMT2-EAR-2 and pMT2-COUP-TFI expression plasmids are kindly provided by Dr John AA Ladias (Harvard Medical School, Boston, Massachusetts, USA). For pSG5-RARg, the cDNA of RARg was generated by PCR using pACT2-RARg as template, and the forward primer, 5'-GGCGAATTCGCCGCCGCCATGGCCACCAA-TAAGGAGC-GA-3' and the reverse primer, 5'-TAGATCT-GGATCCTCAGGATGGGGACTTCAGG-CCCCC-3'. The PCR product was subcloned into the pSG5 at the EcoRI and BamHI sites. pACT2-RARg was obtained from our yeast one-hybrid screening (Yang et al., 1998) . pSG5-ERa was generated by ligating the cDNA of ERa (from pIC-ERf (ATCC)) into the pSG5 vector at the EcoRI site. The correct orientations and sequences of the inserts in pSG5-EAR-2, psG5-COUP-TFI, pSG5-RARg, and pSG5-ERa were con®rmed by both restriction enzyme digestion and direct DNA sequencing.
In vitro translation
The human ERRa-1, EAR-2, COUP-TFI, RARg and ERa proteins were generated in vitro using the TNT-coupled reticulocyte lysate system (Promega, Madison, WI, USA) with T7-RNA polymerase according to the manufacturer's instructions. The reactions were carried out for 90 min at 308C. The relative amounts of the translated ERRa-1, EAR-2, COUP-TFI, RARg and ERa proteins were quanti®ed by [
35 S] methionine (1000 Ci/mmol from Amersham Life Science, Inc.) incorporated into the expressed proteins which were separated on 10% SDS ± PAGE. The expressed proteins on the dried gel were visualized by overnight exposure on Kodak BioMax ®lm (Eastman Kodak Co, Rochester, NY, USA). The translation reaction mixtures (50 ml portions) were snap-frozen and stored at 7708C until use.
DNA mobility shift analysis
As a probe for the mobility shift assay, the double strand S1 oligonucleotide was end-labeled with [g-32 P] ATP using T4 kinase. Mobility shift analysis were performed as described by Singh et al. (1986) . Brie¯y, 3 ml of in vitro expressed ERRa-1 protein or indicated amounts of EAR-2, COUP-TFI, RARg, and ERa proteins (adjusted based on the 35 S radioactivity) were incubated with 6000 c.p.m. of 32 P-labeled probe at room temperature for 30 min in a mixture (15 ml) containing 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 4% (v/v) glycerol, and 0.1 mg/ml poly(dI-dC). For the dose-dependent binding assays of ERRa-1 and COUP-TFI, equal amount of in vitro translated proteins was added into each reaction, and the S1 probe was added in dierent concentrations. The reaction mixture was electrophoresed on 6% acrylamide gels, which were then dried and autoradiographed. Two ®lms were placed against the dried gel, the ®rst one was used to block the 35 S radiation. For competition experiments, the condi-tions used for binding of each protein to the S1 probe were the same as those described above, except that the appropriate amount of the unlabeled DNA fragments and poly(dI-dC) were supplemented in the binding reaction mixture as speci®c and nonspeci®c competitors. The nucleotide sequence of the S1 oligonucleotide used in this analysis is shown below (only sense strand is shown): S1: 5'-ACCAAGGTCAGAAATGCTGCAATTCAAGCCAA-3'.
Yeast one-hybrid assay
To study the estrogen-dependent ERa-S1 interaction, the YM4271 yeast cells were co-transformed with linearized pLacZi-3S1 and pACT2-ERa plasmids. The preparation of these plasmids has been reported (Yang et al., 1998; Zhou et al., 2000) . The ligand, E 2 , was dissolved in DMSO and added to the yeast culture at indicated concentrations with a DMSO concentration of 0.1%. Following 24 h incubation, the cell density was measured at 590 nm absorbance (A 590 ) and the b-galactosidase activity was measured at 420 nm absorbance (A 420 ). To calculate Miller units, the following formula was employed: A 420 [A 590 6incubation time (min)]61000.
Cell transfection and chloramphenicol acetyl transferase (CAT) assay
SK-BR-3 cells were transfected with the CAT plasmids by the use of Lipofectin (Life Technologies, Inc.) according to the manufacturer's instructions. The co-transfection experiments were performed 20 ± 24 h after seeding approximately 4610 5 cells per 60 mm tissue culture dish using 10 mg of the test plasmid and 3 mg of the plasmid pSV-b-Gal which was used to normalize the transfection eciency. After overnight incubation, medium containing lipofectin and DNA were removed, and the cells were cultured in the regular growth medium. After a 24 h incubation, the cells were harvested from the plates by scraping, pelleted by centrifugation, resuspended in 0.25 M Tris-HCl, pH 8.0, and disrupted by freeze-thawing three times. Aliquots of the lysate were used for assay of b-galactosidase activity (Rosenthal, 1987) . The CAT activity in the cell extracts containing an equal amount of b-galactosidase activity from each sample was determined by the liquid scintillation counting (LSC) method (Seed and Sheen, 1988) . Brie¯y, the appropriate amount of cell extract was incubated in a reaction containing 14 C-labeled chloramphenicol and nbutyryl coenzyme A. The reaction products were extracted with a small volume of xylene. The xylene phase was mixed with scintillant and counted in a scintillation counter. The CAT activity was expressed as relative activity compared to that of the pUMSVOCAT construct (1.0) and shown as means+s.e. of three independent transient transfection experiments performed for each construct.
Over expression of EAR-2 and COUP-TF1 in HepG2 cells and aromatase assay
The stable expression plasmids pRC/CMV-EAR-2 and pRC/ CMV-COUP-TF1 were kindly provided by Dr John AA Ladias (Harvard Medical School, Boston, Massachusetts, USA). HepG2 cells were divided into each well of a 6-well plate at 1610 5 cells/well and incubated overnight in Eagle's MEM at 378C, 5% CO 2 with non-essential amino acids, sodium pyruvate and 10% fetal bovine serum. The next day, cell culture medium was changed to Opti-MEM medium. Before transfection, 10 mg of each plasmid DNA was mixed with 20 ml of Lipofectin and incubated at room temperature for 15 min. The cells were incubated with the DNA mixture for 16 h. The medium was then changed with fresh complete medium and the culture was incubated at 378C, 5% CO 2 for 48 h before selection with G418. The selection was started with 500 mg/ml of G418 and the concentration of G418 was gradually increased to 1000 mg/ml over 2 weeks. Individual colonies were picked and subcultured into 25 cm 2¯a sks.
RT ± PCR analysis RNA isolation Total RNA were isolated from 11 cell lines (WS3PF, WS3TF, GI33PF, GI33TF, W88-TF, Hep-G2, MDA-MB-231, MCF-7, SK-BR-3, MCF-10A, HBL-100) and 55 breast cancer tissue specimens with the one step method described by Chomczymski (1998) . All RNAs were treated with RNase-free DNase I in order to get rid of the minor contamination of genomic DNA. WS3PF, WS3TF, GI33PF, GI33TF, and W88-TF are human breast ®broblast cell lines. HepG2 is a human hepatoma cell line. MDA-MB-231, MCF-7, and SK-BR-3 are human breast cancer cell lines, and MCF-10A and HBL-100 are non-cancer breast epithelial cell lines. These epithelial cell lines were obtained from ATCC. Fifty-®ve primary breast carcinoma samples were collected during surgery and were frozen immediately in liquid nitrogen. The tissue specimens were stored at 7708C until they were analysed.
Precautions were taken to make sure that our RNA preparations did not contain DNA. The RNA preparations were treated with RNAse-free DNase. In addition, a control such as PCR analysis with RNA, without RT, was performed to assure us that the PCR products are derived from mRNA.
RT ± PCR
The semi-quantitative analyses were performed using the Titan one tube RT ± PCR system (Roche Molecular Biochemical, Indianapolis, IN, USA). We performed 25 cycles of PCR, a non-saturating condition. This allowed us to compare the relative expression levels of nuclear receptors in our samples. It has been shown that with 25 cycles, product accumulation is exponential . All samples were ®rst analysed using b-actin primers, and the RNA levels for the analyses of nuclear receptors and aromatase were normalized based on results from analyses with b-actin primers. The RT ± PCR conditions used are shown as below. After a 1 h incubation at 508C, 25 cycles of PCR were performed at 948C for 30 sec, 508C for 1 min, and 688C for 2 min. The reaction concluded with a 7 min elongation period at 688C. Primers for our RT ± PCR analyses are shown below.
Southern transfer
The RT ± PCR products (10 ml each) were run on 1.5% agarose gel, transferred to the positively charged Zeta membrane (Bio-Rad Laboratories, Hercules, CA, USA) in 206SSC, and UV-cross linked.
Hybridization
All probes were labeled with DIG-11-ddUTP using to the 3'-end oligonucleotide labeling kit (Roche Molecular Biochemical, Indianapolis, IN, USA). The blots were prehybridized in DIG-Easy-Hyb (Roche Molecular Biochemical, Indianapolis, IN, USA) for 1 h and hybridized overnight at dierent hybridization temperatures with dierent probes. The hybridization temperature was generally 5 ± 10 degrees below probe's melting temperature. After hybridization, the blots were washed twice for 1 min in 26SSC, 0.1% SDS and twice for 15 min in 0.16SSC, 0.1% SDS.
Chemiluminescent detection
The RT ± PCR products were detected using standard procedures. Brie¯y, after hybridization and washes, membranes were rinsed in washing buer (maleic acid buer). The membranes were incubated for 30 min in blocking solution, then in anti-DIG-AP (1 : 10 000) solution for 30 min, incubated twice for 15 min in washing buer, and equilibrated for 2 min in detection buer. CSPD 1 ready-to-use solution was applied to the membranes followed by incubation for 5 min at room temperature. After incubation for 15 min at 378C, the membranes were exposed to Lumi-®lm Chemiluminescent detection ®lm (Roche Molecular Biochemical, Indianapolis, IN, USA) for 15 ± 30 min at room temperature. Image density was quanti®ed with an Imaging Densitometer (Model GS-670, Bio-Rad, Hercules, CA, USA).
